Immunocore: strategic priorities, pipeline expansion ahead of 42nd Annual J.P. Morgan

 Increasing commercial access to KIMMTRAK (tebentafusp-tebn) globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma

Multiple clinical readouts expected to start in 2Q 2024 for IMC-F106C (PRAME HLA-A02) from Phase 1/2 clinical trial monotherapy and combination arms; IMC-P115C (PRAME HLA-A02 HLE) and IMC-T119C (PRAME HLA-A24) ImmTAC candidates on track for expected CTA/IND submission in 2024

Submitted clinical trial applications (CTA) for IMC-R117C, a first-in-class ImmTAC targeting PIWIL1 for colorectal and other gastrointestinal cancers

Data from IMC-M113V Phase 1 clinical trial in people living with HIV expected in the second half of 2024

Advancing novel TCR bispecific candidates for autoimmune diseases

Company to present at 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 AM P.T. / 5:00 PM GMT

https://www.globenewswire.com/news-release/2024/01/05/2804565/0/en/Immunocore-announces-strategic-priorities-and-pipeline-expansion-ahead-of-42nd-Annual-J-P-Morgan-Healthcare-Conference-presentation.html